suprelorin 4.7 mg
virbac (australia) pty ltd - deslorelin as deslorelin acetate - parenteral implant, device - deslorelin as deslorelin acetate ungrouped active 4.7 mg/im - endocrine system - dog - male - reducing testosterone production
suprelorin 4.7mg
virbac new zealand limited - deslorelin - deslorelin 93.88 g/kg - endocrine agent (hormone)
suprelorin 9.4 mg
virbac (australia) pty ltd - deslorelin as deslorelin acetate - parenteral implant, device - deslorelin as deslorelin acetate ungrouped active 9.4 mg/im - endocrine system - dog - male - reducing testosterone production
suprelorin
virbac s.a. - deslorelin acetate - pituitary and hypothalamic hormones and analogues - dogs; ferrets - for the induction of temporary infertility in healthy, entire, sexually mature male dogs and ferrets.
suprelorin 4.7 mg implant
virbac ah, inc. - deslorelin (deslorelin acetate) - implant - 4.7mg - deslorelin (deslorelin acetate) 4.7mg - dogs
suprelorin f- deslorelin acetate implant
virbac ah, inc. - deslorelin acetate (unii: 679007nr5c) (deslorelin - unii:tkg3i66tve) - deslorelin acetate 4.7 mg - suprelorin® f (4.7 mg) implant is indicated for the management of adrenal gland cortical disease in the male and female domestic ferret. do not use this product in ferrets with known hypersensitivity to deslorelin acetate or other synthetic hormones.
suprelorin 4.7 mg implant for dogs and cats
virbac - deslorelin - implant - hormone - cats, dogs
suprelorin 9.4 mg implant for dogs and ferrets
virbac - deslorelin - implant - hormone - dogs, ferrets
suprelorin 4.7 mg implant
virbac rsa (pty) ltd - implant - see ingredients - each implant contains deslorelin 4.7 mg - c 25.2. hormones
supprelin la- histrelin acetate implant
endo pharmaceuticals inc. - histrelin acetate (unii: qmg7hld1ze) (histrelin - unii:h50h3s3w74) - histrelin acetate 50 mg - supprelin la (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (cpp). children with cpp (neurogenic or idiopathic) have an early onset of secondary sexual characteristics (earlier than 8 years of age in females and 9 years of age in males). they also show a significantly advanced bone age that can result in diminished adult height attainment. prior to initiation of treatment a clinical diagnosis of cpp should be confirmed by measurement of blood concentrations of total sex steroids, luteinizing hormone (lh) and follicle stimulating hormone (fsh) following stimulation with a gnrh analog, and assessment of bone age versus chronological age. baseline evaluations should include height and weight measurements, diagnostic imaging of the brain (to rule out intracranial tumor), pelvic/testicular/adrenal ultrasound (to rule out steroid secreting tumors), human chorionic gonadotropin levels (to rule out a chorionic gonadotropin secreting tumor), and adre